Dexcom Inc (Dexcom) designs, develops and commercializes continuous glucose monitoring (CGM) systems used by people with diabetes and healthcare providers in the hospital. The company’s major products include integrated Dexcom G6 CGM system, Dexcom Share remote monitoring system, Dexcom Real-Time API, Dexcom ONE CGM system, associated software and mobile apps. It provides Dexcom Care training to users of CGM system and other support services. The company offers products to endocrinologists, physicians, diabetes educators and others. It distributes products directly in the US, Austria, Canada, Germany, Switzerland and the UK, and also through a network of distributors in Australia, the US, New Zealand, and other countries in Asia, Europe, Africa, Latin America, and the Middle East. Dexcom is headquartered in San Diego, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company DexCom Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- DexCom Inc Company Overview
- DexCom Inc Company Snapshot
- DexCom Inc Pipeline Products and Ongoing Clinical Trials Overview
- DexCom Inc - Pipeline Analysis Overview
- Business Description
- DexCom Inc - Key Facts
- DexCom Inc - Major Products and Services
- DexCom Inc Pipeline Products by Development Stage
- DexCom Inc Ongoing Clinical Trials by Trial Status
- DexCom Inc Pipeline Products Overview
- ABC4D
- ABC4D Product Overview
- ACHIEVE mHealth App
- ACHIEVE mHealth App Product Overview
- ACHIEVE mHealth App Clinical Trial
- DexCom CGM With Accu-Chek Insulin Delivery System
- DexCom CGM With Accu-Chek Insulin Delivery System Product Overview
- Dexcom G7 CGM System
- Dexcom G7 CGM System Product Overview
- Dexcom G7 CGM System Clinical Trial
- Dexcom Hospital Continuous Glucose Monitoring System
- Dexcom Hospital Continuous Glucose Monitoring System Product Overview
- First-Gen Verily Sensor
- First-Gen Verily Sensor Product Overview
- inControl
- inControl Product Overview
- inControl Clinical Trial
- Touchscreen Receiver
- Touchscreen Receiver Product Overview
- DexCom Inc - Key Competitors
- DexCom Inc - Key Employees
- DexCom Inc - Key Employee Biographies
- DexCom Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- DexCom Inc, Recent Developments
- Aug 26, 2024: Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available
- Aug 14, 2024: Ramq Expands Provincial Coverage To Include Dexcom G7, Bringing The Next-generation CGM System To More Québec Residents
- Jul 29, 2024: Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada
- Jun 20, 2024: Dexcom Expands AID Partnership Into The Netherlands
- Jun 20, 2024: Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
- Jun 05, 2024: Dexcom G7 Now Connects Directly to Apple Watch in the U.S.
- Jun 03, 2024: Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems
- May 20, 2024: Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
- May 16, 2024: Bio Conscious Announces Strategic API Integration with Dexcom That Will Elevate the Current Level of Care for Diabetes Patients in Clinical Settings
- May 08, 2024: DexCom Receives Additional 510(K) Clearance For Dexcom G7 CGM System
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- DexCom Inc Pipeline Products and Ongoing Clinical Trials Overview
- DexCom Inc Pipeline Products by Equipment Type
- DexCom Inc Pipeline Products by Indication
- DexCom Inc Ongoing Clinical Trials by Trial Status
- DexCom Inc, Key Facts
- DexCom Inc, Major Products and Services
- DexCom Inc Number of Pipeline Products by Development Stage
- DexCom Inc Pipeline Products Summary by Development Stage
- DexCom Inc Ongoing Clinical Trials by Trial Status
- DexCom Inc Ongoing Clinical Trials Summary
- ABC4D - Product Status
- ABC4D - Product Description
- ACHIEVE mHealth App - Product Status
- ACHIEVE mHealth App - Product Description
- ACHIEVE mHealth App - ACHIEVE: Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching
- DexCom CGM With Accu-Chek Insulin Delivery System - Product Status
- DexCom CGM With Accu-Chek Insulin Delivery System - Product Description
- Dexcom G7 CGM System - Product Status
- Dexcom G7 CGM System - Product Description
- Dexcom G7 CGM System - Accuracy of the Dexcom G7 Continuous Glucose Monitoring System Following Cardiac Surgery
- Dexcom G7 CGM System - Can "Continuous Glucose Monitors" (CGMS) Improve Postpartum (PP) Gestational Diabetes (GDM) Screening for Diabetes?
- Dexcom G7 CGM System - Concordance of Hypoglycemia Measurement in People With Type 1 Diabetes, With Simultaneous Use of Two Devices for Continuous Glucose Measurement: Abbott Freestyle Libre 2 and Dexcom G7
- Dexcom G7 CGM System - Continuous Glucose Monitoring in the Intensive Care Unit: Validation and Implementation
- Dexcom G7 CGM System - Continuous Glucose Monitoring in Treatment of Postprandial Hypoglycemia After Bariatric Surgery: The HypoBar Randomized Clinical Trial
- Dexcom G7 CGM System - Dexcom Continuous Glucose Monitoring System Use in a Real-World, Global Registry
- Dexcom G7 CGM System - Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus
- Dexcom G7 CGM System - The Effect of Continuous Glucose Monitoring With Real-time Alerts on Glycaemic Control in Surgical Patients with Diabetes: A Randomized, Clinical Multicentre Trial
- Dexcom Hospital Continuous Glucose Monitoring System - Product Status
- Dexcom Hospital Continuous Glucose Monitoring System - Product Description
- First-Gen Verily Sensor - Product Status
- First-Gen Verily Sensor - Product Description
- inControl - Product Status
- inControl - Product Description
- inControl - Feasibility of Automated Insulin Delivery with an Interoperable Algorithm Using an Alternative Insulin Pump
- Touchscreen Receiver - Product Status
- Touchscreen Receiver - Product Description
- DexCom Inc, Key Employees
- DexCom Inc, Key Employee Biographies
- DexCom Inc, Subsidiaries
- Glossary
- DexCom Inc Pipeline Products by Equipment Type
- DexCom Inc Pipeline Products by Development Stage
- DexCom Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Roche Diagnostics International Ltd
- Abbott Diabetes Care Inc
- LifeScan Inc
- Becton Dickinson and Co
- Ascensia Diabetes Care US Inc
- Medtronic Diabetes
